No Data
Yantai Dongcheng Biochemicals (002675.SZ): The APN-1607 product has currently communicated with the CDE prior to the NDA, and its safety and efficacy have been recognized.
On March 5, Glonghui reported that Yantai Dongcheng Biochemicals (002675.SZ) recently stated in its investor relations activities that communication with CDE regarding the APN-1607 product has been conducted before the NDA, and its safety and efficacy have been recognized. However, based on the improvements in domestic drug release regulations and the increase in review requirements, additional impurity research and other work will be carried out before the product launch.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Earnings Miss: Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Missed EPS By 26% And Analysts Are Revising Their Forecasts
Dongcheng Pharmaceutical: 2024 Annual Report Summary
Dongcheng Pharmaceutical: 2024 Annual Report
Yantai Dongcheng Biochemicals (002675.SZ): Net income in 2024 is 0.184 billion yuan, a year-on-year decline of 12.35%.
On February 26, Gelonghui reported that Yantai Dongcheng Biochemicals (002675.SZ) published its annual report for 2024, indicating that the company achieved revenue of 2.869 billion yuan for the year 2024, a decrease of 12.42% year-on-year; the net income attributable to shareholders of the listed company was 0.184 billion yuan, down 12.35% year-on-year, mainly due to: revenue declining by 12.42% year-on-year. During the reporting period, the nuclear medicine business sector generated sales revenue of 1.012 billion yuan, a decrease of 0.52% year-on-year, among which key product 18F-FDG achieved revenue of 0.421 billion yuan, an increase of 0.25% year-on-year; Yunke injection solution generated revenue.
Why We're Not Concerned About Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Share Price
